Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone growth

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    820 result(s) found for: Bone growth. Displaying page 1 of 41.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-004316-73 Sponsor Protocol Number: 3189 Start Date*: 2006-08-23
    Sponsor Name:Royal Liverpool University hospital
    Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ...
    Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002991-40 Sponsor Protocol Number: A6281269 Start Date*: 2015-04-01
    Sponsor Name:Pfizer Inc
    Full Title: Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study
    Medical condition: Growth Disorders, Growth Retardation
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019296-30 Sponsor Protocol Number: Start Date*: 2010-05-18
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degre...
    Medical condition: ALS (acid label subunit) deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth Hormone Deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003100-39 Sponsor Protocol Number: NSGA Start Date*: 2013-11-28
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc...
    Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001020-36 Sponsor Protocol Number: MS301 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATI...
    Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000647-14 Sponsor Protocol Number: 15782601 Start Date*: 2016-05-23
    Sponsor Name:University Hospital Toulouse
    Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial
    Medical condition: Noonan syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004525-41 Sponsor Protocol Number: 14VR4 Start Date*: 2015-04-10
    Sponsor Name:Versartis, Inc.
    Full Title: Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children w...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001095-11 Sponsor Protocol Number: MS308 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL
    Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001695-34 Sponsor Protocol Number: LUM-201-04 Start Date*: 2022-09-08
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children with Idiopathic Growth Hormone Deficiency who have Previou...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004835-72 Sponsor Protocol Number: UB-MedSci-001/2004 Start Date*: 2005-01-12
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham Foundation NHS Trust
    Full Title: A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults
    Medical condition: Growth hormone deficiency in adult life
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002992-17 Sponsor Protocol Number: A6281271 Start Date*: 2015-05-14
    Sponsor Name:Pfizer, Inc.
    Full Title: EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM®
    Medical condition: Growth retardation related to long-term glucocorticoid therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10053759 Growth retardation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-001313-14 Sponsor Protocol Number: 2007-189-2 Start Date*: 2012-10-17
    Sponsor Name:Dutch growth research foundation
    Full Title: Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS.
    Medical condition: Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10041331 Somatotrophin LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002224-15 Sponsor Protocol Number: Start Date*: 2009-01-09
    Sponsor Name:Göteborgs Universitet
    Full Title: Individual GH dosing using 1st year GH responsiveness for prepubertal growth response in short GHD/ISS children
    Medical condition: GHD+ISS in prepubertal children born at term or prematurely, AGA or SGA GHD and SGA children (phase IV study) ISS children (phase III study)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002507-32 Sponsor Protocol Number: IBD8 Start Date*: 2004-10-11
    Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division
    Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with Inflammatory bowel disease (IBD) and growth failure.
    Medical condition: Growth retardation secondary to inflammatory bowel disease in children
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004153-25 Sponsor Protocol Number: JIA6 Start Date*: 2004-12-10
    Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division
    Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure.
    Medical condition: Growth retardation secondary to juvenile idiopathic arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000446-56 Sponsor Protocol Number: CRT076 Start Date*: 2016-03-07
    Sponsor Name:Cristália Produtos Químicos Farmacêuticos Ltda.
    Full Title: Clinical study to compare recombinant human growth hormone Cristalia (r-hGH Cristalia) versus Genotropin® in prepubertal children with growth deficiency due to deficiency of growth hormone.
    Medical condition: Growth deficiency due to growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-001674-32 Sponsor Protocol Number: NordiNet-IOS Start Date*: 2009-04-29
    Sponsor Name:Novo Nordisk Farma Oy
    Full Title: NordiNet International Outcome Study (NordiNet IOS)
    Medical condition: Small Gestation Age, Turner Syndrome, Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-000231-27 Sponsor Protocol Number: NN8640-4263 Start Date*: 2019-04-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Trial now transitioned) DK (Completed) AT (Trial now transitioned) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Ongoing) IE (Completed) EE (Completed) LV (Trial now transitioned) PL (Trial now transitioned) HU (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016783-37 Sponsor Protocol Number: WS475202 Start Date*: 2010-01-07
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The Effects of 18-Month Replacement with a Very Low Fixed Dose vs. Standard Dose of Growth Hormone (GH) on Insulin Sensitivity, Body Composition, Bone Mass, Lipids, Muscle Strength and Quality of L...
    Medical condition: Growth hormone deficiency in adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000914-47 Sponsor Protocol Number: GHLIQUID-1517 Start Date*: 2017-05-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A long-term, multi-centre, randomised, controlled, double-blind, parallel-group trial, investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for ges...
    Medical condition: Foetal growth problem Small for Gestational Age Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 17:10:00 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA